Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed - guidance (TA375)
- National Institute for Health and Care Excellence - NICE
- Publication date:
- 26 January 2016
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication.
Is this guidance up to date?
We reviewed the evidence in September 2019 and we are updating the guidance for people with moderate disease.
There is a simple discount patient access scheme for abatacept. Contact UKCommercialEnquiries@bms.com for details.
There is a complex patient access scheme for certolizumab pegol. Contact UCBCares.UK@ucb.com for details.
There is a complex patient access scheme for golimumab. Contact email@example.com for details.
There is a simple discount patient access scheme for tocilizumab. Contact Welwyn.firstname.lastname@example.org for details.
Guidance development process
This guidance replaces NICE technology appraisal guidance on:
- adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)
- certolizumab pegol for the treatment of rheumatoid arthritis (TA186)
- golimumab for the treatment of methotrexate-naive rheumatoid arthritis (TA224) and
- abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA280).
It partially updates golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225) and tocilizumab for the treatment of rheumatoid arthritis (TA247).